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INTRODUCTION: During the past 20 years, the
approval of anticoagulants such as low-molecular-weight
heparins (LMWHs), indirect factor Xa inhibitors and direct
thrombin inhibitors has signaled a growing interest in
antithrombotic compounds that have relatively discrete
targets within the coagulation pathway.
MATERIAL AND METHOD: A Medline and an extensive
hand search were performed on English-language
publications beginning in 1971 till now. The pertinent
literature and clinical protocols of hospital dentistry
departments have been extensively reviewed, presented
and discussed.
CONCLUSION:
 The currently available anticoagulant agents all target
thrombin or FXa, either indirectly or directly. Thrombin
is a logical target because of its multiple roles in
coagulation.
 The management of oral surgery procedures on patients
treated with new anticoagulants should be influenced by
several factors: laboratory values, extent and urgency of
the intervention, treating physician’s recommendation,
available facilities, dentist expertise, and patient’s oral,
medical, and general condition.
RESULTS: Several evolving clinical practices in the last 
years have been detected: 
∆ anticoagulants are generally not discontinued, 
∆ oral surgery is performed despite laboratory values 
showing significant bleeding tendency,
∆ new effective local hemostatic modalities are used to 
prevent bleeding,
∆ patients at risk are referred to hospital-based clinics.
Figure 1. Injury to the vessel wall is considered to be the primary stimulus
that sets coagulation in motion. Vessel injury may be mechanical, chemical, or
electrical. In arteries, vessel injury is mainly due to the rupture of an
atherosclerotic plaque, resulting in disruption of the endothelium and
exposure of plaque constituents to the blood. In veins, vessel wall disruption
is a less important trigger of coagulation, although vessel wall injury can
occur in the setting of surgery or with indwelling central venous catheters.
More common triggers are reduced blood flow (stasis), altered properties of
the blood that render it more prone to clotting (thrombophilia), and/or
alterations in the endothelium.
Figure 2.The limitations of warfarin prompted the search for
new oral anticoagulants that can be given in fixed doses without the need
for routine coagulation monitoring. The agents in most advanced stages of
development target either thrombin or Fxa. Two such agents, dabigatran
etexilate and rivaroxaban, have already been licensed in Europe and Canada
(but not currently in the United States) for thromboprophylaxis after
elective hip or knee replacement surgery. A third agent, apixaban, is under
investigation for this indication.
Dabigatran Etexilate Apixaban Rivaroxaban
Target Thrombin Factor Xa Factor Xa
Prodrug Yes No No
Dosing Fixed, once daily Fixed, twice daily Fixed, once daily
Bioavailability (%) 6 50 80
Monitoring No No No
Half-life (h) 12-14* 12.7 7-11
Renal clearance (%) 80 25 65
Interactions P-gp inhibitors** Potent CYP3A4 
inhibitors†
Combined P-gp
inhibitors +
CYP3A4 inhibitors†
*In healthy volunteers, 14-17 hours in patients undergoing major orthopaedic surgery.
**P-glycoprotein (P-gp) inhibitors include verapamil, clarithromycin, and quinidine. 
Quinidine is contraindicated in patients receiving dabigatran.
†Cytochrome P450 (CYP) 3A4 inhibitors include ketoconazole, macrolide antibiotics, and 
protease inhibitors.
Table 1. Pharmacologic Features of Dabigatran Etexilate, Rivaroxaban, and Apixaban
Gross PL, et al. Clin Pharmacol Ther. 2009;86:139-146.
AIM: of this study is to review the evidence of different
therapy approach, to highlight the areas of major concern,
and to suggest specific oral surgery treatment for patients
on new oral anticoagulants.
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